Perspective Therapeutics reports 44% ORR in [212Pb]VMT-α-NET trial; cash $174.1M

Perspective Therapeutics, Inc.

Phase 1/2a data: 44% objective response rate (7/16) in Cohort 2 patients with SSTR2+ all tumors at median 41-week follow-up.
No dose-limiting toxicities, treatment-related discontinuations, or Grade 4/5 adverse events observed across 55 treated patients.
14 of 16 Cohort 2 patients with SSTR2+ all tumors remain progression-free and on study (87.5%).
Preliminary cash, cash equivalents and short-term investments ~$174.1M as of Sep 30, 2025, funding operations into late 2026.
Initial efficacy data for additional 31 patients expected in 2026; company plans registration study based on emerging profile.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.